#3-78E. Unveiling CPPD: Beyond Pseudogout and Osteoarthritis (LancetRheum, 2024)

Are you frequently misdiagnosing inflammatory arthritis in your elderly patients as routine osteoarthritis or seronegative rheumatoid arthritis? This episode explores calcium pyrophosphate deposition (CPPD) disease, a prevalent yet widely under-recognized immune-mediated arthropathy triggered by CPP crystals. This comprehensive review covers the disease's intricate pathophysiology, its diverse clinical phenotypes—ranging from acute flares to persistent chronic arthritis—and the latest diagnostic imaging modalities like ultrasonography. A pivotal advancement highlighted in this paper is the introduction of the 2023 ACR/EULAR classification criteria, which offer the first validated framework to accurately identify and differentiate CPPD's varied presentations. However, when critically appraising the management guidelines, it is crucial to note that evidence for treating chronic CPPD remains weak; most long-term therapies rely heavily on expert consensus and off-label use rather than high-quality randomized controlled trials. For practicing physicians, this paper is highly relevant as it equips you with the latest diagnostic criteria and imaging insights needed to avoid common misdiagnoses, ensuring your elderly patients receive optimal, tailored management for their specific CPPD phenotype.

Citation: Pascart T, Filippou G, Lioté F, Sirotti S, Jauffret C, Abhishek A. Calcium pyrophosphate deposition disease. The Lancet Rheumatology. 2024. DOI: 10.1016/S2665-9913(24)00122-X

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.